Molecular basis for inhibiting human glucose transporters by exofacial inhibitors

Human glucose transporters (GLUTs), particularly GLUT1 and GLUT3, are potential anticancer therapy targets. Here, Nan Wang et al. use an engineered GLUT 3 variant to identify an exofacial GLUT3 inhibitor, SA47, and elucidate the drug’s inhibitory mechanism.

書誌詳細

出版年:	Nature Communications
主要な著者:	Nan Wang, Shuo Zhang, Yafei Yuan, Hanwen Xu, Elisabeth Defossa, Hans Matter, Melissa Besenius, Volker Derdau, Matthias Dreyer, Nis Halland, Kaihui Hu He, Stefan Petry, Michael Podeschwa, Norbert Tennagels, Xin Jiang, Nieng Yan
フォーマット:	論文
言語:	英語
出版事項:	Nature Portfolio 2022-05-01
オンライン･アクセス:	https://doi.org/10.1038/s41467-022-30326-3